CytomX Therapeutics Profit Margin

CytomX Therapeutics (CTMX) currently reports a profit margin of -435.21% as of June 2026. That compares with 34.01% in the prior-year period — down 1379.8% year over year. That is below the Healthcare sector average of 13.89%. Use the charts on this page to explore CytomX Therapeutics's profit margin history and peer comparisons.

CytomX Therapeutics's profit margin decreased from 34.01% to -435.21% — a 1379.8% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

CytomX Therapeutics's profit margin of -435.21% is lower than the Healthcare sector average of 13.89%. That is roughly 3232.6% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but CytomX Therapeutics's current -435.21% should be judged against Healthcare norms (sector average: 13.89%) and against CTMX's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -435.21%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 13.89%. From there, open related valuation or income-statement pages for CytomX Therapeutics, and consider following CTMX for alerts when major investors trade the stock.